Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
23 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Epistem Holdings Plc - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Epistem Holdings Plc - Product Pipeline Review - 2015', provides an overview of the Epistem Holdings Plc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Epistem Holdings Plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Epistem Holdings Plc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Epistem Holdings Plc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Epistem Holdings Plc's pipeline products Reasons To Buy - Evaluate Epistem Holdings Plc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Epistem Holdings Plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Epistem Holdings Plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Epistem Holdings Plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Epistem Holdings Plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Epistem Holdings Plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Epistem Holdings Plc Snapshot 5 Epistem Holdings Plc Overview 5 Key Information 5 Key Facts 5 Epistem Holdings Plc - Research and Development Overview 6 Key Therapeutic Areas 6 Epistem Holdings Plc - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Epistem Holdings Plc - Pipeline Products Glance 12 Epistem Holdings Plc - Early Stage Pipeline Products 12 Discovery Products/Combination Treatment Modalities 12 Epistem Holdings Plc - Drug Profiles 13 Epi-1461 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Epi-2499 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Epi-3423 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Epi-5539 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Epi-5540 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Epistem Holdings Plc - Pipeline Analysis 18 Epistem Holdings Plc - Pipeline Products by Molecule Type 18 Epistem Holdings Plc - Dormant Projects 19 Epistem Holdings Plc - Company Statement 20 Epistem Holdings Plc - Locations And Subsidiaries 21 Head Office 21 Other Locations & Subsidiaries 21 Appendix 22 Methodology 22 Coverage 22 Secondary Research 22 Primary Research 22 Expert Panel Validation 22 Contact Us 22 Disclaimer 23
List of Tables
Epistem Holdings Plc, Key Information 5 Epistem Holdings Plc, Key Facts 5 Epistem Holdings Plc - Pipeline by Indication, 2015 7 Epistem Holdings Plc - Pipeline by Stage of Development, 2015 8 Epistem Holdings Plc - Monotherapy Products in Pipeline, 2015 9 Epistem Holdings Plc - Partnered Products in Pipeline, 2015 10 Epistem Holdings Plc - Partnered Products/ Combination Treatment Modalities, 2015 11 Epistem Holdings Plc - Discovery, 2015 12 Epistem Holdings Plc - Pipeline by Molecule Type, 2015 18 Epistem Holdings Plc - Dormant Developmental Projects,2015 19 Epistem Holdings Plc, Subsidiaries 21
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.